Sanofi Canada invests in prostate cancer research
Collaboration with the GU Radiation Oncology Group of Quebec and the Segal Cancer Centre at the Jewish General Hospital (JGH)
Sanofi Canada is supporting a five-year study on radiation therapy and prostate cancer. Dr. Tamim Niazi of the Quebec Radiation Oncology GU Group and the JGH is the lead researcher. Sanofi Canada President and CEO, Hugh O'Neill and members of Sanofi's Oncology Team celebrate the collaboration.

CNW Group/SANOFI CANADA
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.